Quantitative proteomics for drug toxicity
Quantitative proteomics for drug toxicity
复制标题
DOI：
10.1093/bfgp/elp006
复制
发表时间：
2009-03-01
期刊：
影响因子：
--
通讯作者：
Yu, Li-Rong
中科院分区：
文献类型：
--
作者：
Gao, Yuan;Holland, Ricky D.;Yu, Li-Rong
定量蛋白质组学技术及其在毒理学中不断增加的应用极大地推进了毒物蛋白质组学的新兴领域。该学科专注于有毒物质引起的毒性的蛋白质组学研究，包括但不限于药物、毒素、环境压力源、化学品和任何其他引起显着病理反应的材料。药物安全性是开发阶段和临床应用过程中关注的重点。毒性生物标志物的鉴定、潜在的药物靶点和毒性机制的表征是药物开发和评价过程中定量毒物蛋白质组学的主要研究领域。定量蛋白质组学方法的进一步发展和应用将极大地促进个性化医疗的实现。
The emerging field of toxicoproteomics has been greatly advanced by quantitative proteomic technologies and their increasing applications in toxicology. The discipline is focused on the proteomic study of toxicity caused by toxic substances, including but not limited to drugs, toxins, environmental stressors, chemicals and any other materials that induce significant pathological responses. Drug safety is a major point of concern during the development phase and clinical application. Identification of toxicity biomarkers, potential drug targets and characterization of toxicity mechanisms represent major research areas for quantitative toxicoproteomics during drug development and evaluation. Further development and application of quantitative proteomic approaches would significantly facilitate the realization of personalized medicine.